Lilly, Boehringer collaborate on diabetes drugs

(AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.

Lilly, based in Indianapolis, loses patent protection this year for its top-selling drug, the anti-psychotic Zyprexa, and faces the loss of some other key patents in the next few years. The drugmaker said Tuesday that the deal with Boehringer Ingelheim offers the potential of boosting near-term revenue.

Lilly could receive more than $1 billion in future payments depending on how well the collaboration performs and whether the drugs under development reach certain sales milestones. Boehringer Ingelheim will be eligible for future payments totaling about $807 million.

The collaboration includes two Lilly insulins expected to enter late-stage testing this year and a type 2 diabetes treatment from Boehringer Ingelheim that is being reviewed by regulators.

Shares of Eli Lilly and Co. rose slightly in premarket trading.

Explore further: Merck ends development of Parkinson's disease drug

Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Driving and hands-free talking lead to spike in errors, study shows

Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.

Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.

Going live: Immune cell activation in multiple sclerosis

Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...

Galaxies fed by funnels of fuel

(Phys.org) —Computer simulations of galaxies growing over billions of years have revealed a likely scenario for how they feed: a cosmic version of swirly straws.

Experiment investigates how classical physics may emerge from quantum physics

(Phys.org) —In order to better understand how the laws governing the quantum and classical regimes are related to one another, physicists have performed an experiment allowing them to observe a quantum-to-classical ...

The better to see you with: Scientists build record-setting metamaterial flat lens

For the first time, scientists working at the National Institute of Standards and Technology have demonstrated a new type of lens that bends and focuses ultraviolet (UV) light in such an unusual way that ...

Google eyes emerging markets networks

Google has become deeply involved in a series of projects to build and operate wireless networks in emerging markets including sub-Saharan Africa and Southeast Asia, a report said Friday.

New analysis yields improvements in a classic 3D imaging technique

Research conducted at Curtin University in Perth has enabled significant increases in image quality in a widely used 3D printing technique that is more than 100 years old.

DanielHaszard

not rated yet Jan 11, 2011

Zyprexa damage Claims Still Unresolved-

Eli Lilly's #1 cash cow Zyprexa drug sale $38 billion dollars to date has a greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company also is a big profiteer of diabetes treatment.

All the best for Eli Lilly and resolution of Zyprexa claims
--Daniel Haszard Zyprexa victim activist

Lilly, Boehringer collaborate on diabetes drugs

Jan 11, 2011

Tests find Rossi's E-Cat has an energy density at least 10 times higher than any conventional energy source

Observations of stellar visibility by citizen scientists accurately measure the brightness of the night sky

Physicists develop revolutionary low-power polariton laser

Comprehensive analysis of impact spherules supports theory of cosmic impact 12,800 years ago

Northern hemisphere losing last dry snow region, says study

Related Stories

Eli Lilly halts development of Alzheimer's drug

Mississippi sues pharmaceutical company

Mississippi sues pharmaceutical company

Eli Lilly may drop inhaled insulin plan

German firm shelves libido-boosting drug for women

FDA clears Eli Lilly's blood thinner Effient

Recommended for you

Merck ends development of Parkinson's disease drug

J&J expects 10-plus new drug applications by 2017

Experts favor US approval of Merck sleeping pill (Update)

Glaxo, US partnering to develop new antibiotics

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

Succesful results in developing oral vaccine against diarrhea

User comments : 1